Estrogen and progesterone receptor mrna levels in primary breast cancer: Association with patient survival and other clinical and tumor features

Abstract

The relative expression of estrogen receptor (ER) and progesterone receptor (PR) mRNA transcripts was measured in 71 primary breast‐cancer biopsies. ER and PR binding activity were estimated in parallel by the dextran‐coated‐charcoal method. There was a close correlation between the amount of ER mRNA and estradiol binding activity. Tumors from post‐menopausal patients contained higher levels of ER mRNA than those from pre‐menopausal patients. Northern‐blot analysis indicated the presence of a major band of 6.3 kb in all ER mRNA‐positive tumors. Some tumors showed, in addition, 3,7‐ and 2.4‐kb transcripts. PR binding activity and overall PR mRNA levels correlated moderately. PR mRNA and ER mRNA were associated. Four PR mRNA species with estimated sizes of 11.4, 4.5, 3.7 and 2.5 kb were detected in 14% of the PR mRNA‐positive tumors. The 3.7‐kb transcript was detected to varying degrees in all PR mRNA‐positive biopsies, accompanied in some tumors by the 2.5‐kb species. ER and PR mRNA levels < 50 pg/5 μg total RNA correlated with prolonged survival of the patients. In addition, high ER mRNA levels were associated with absence of necrosis and vascular invasion together with absence or minimal level of tumor lymphocytic infiltration, but not with age, clinical stage, tumor size or overexpression of c‐myc or c‐erbB‐2 mRNA. PR mRNA was not statistically associated with any of the above clinicopathological features. A bivariate analysis showed that both ER and PR mRNA levels were able to predict overall survival independently of the lymph‐node status.